Adam Waldman, Chief Commercialization Officer, said Briumvi is being priced to be "the lowest priced, branded disease modifying therapy approved for MS." Comments from TG Therapeutics’ Briumvi FDA approval call and associated slides.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX: